SCHEMBL19436616

SCHEMBL19436616

CCOC(=O)c1cnn2c(C)cc(-c3cccc(OCC)c3)nc12

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 0.77
KDM4E B2RXH2 7/20 0.77
HPGD P15428 6/20 0.77
ALDH1A1 P00352 5/20 0.77
NPC1 O15118 5/20 0.77
RAB9A P51151 5/20 0.77
SMN1; SMN2 Q16637 4/20 0.77
CASP1 P29466 2/20 0.58
CASP7 P55210 2/20 0.58
TSHR P16473 1/20 0.58
CSNK1D P48730 5/20 0.52
MAPT P10636 3/20 0.52
THRB P10828 1/20 0.51
GLA P06280 1/20 0.50
GAA P10253 1/20 0.50
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TP53 P04637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29929515 1.00 HSD17B10 (0.77) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL19436687 0.92 ALDH1A1 (0.77) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL29929434 0.92 ALDH1A1 (0.77) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL19436691 0.92 KDM4E (0.66) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL19436611 0.89 HPGD (0.70) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL29929731 0.89 HPGD (0.70) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL14014114 0.88 KDM4E (0.78) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL29930116 0.88 HSD17B10 (0.71) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL19436657 0.88 HSD17B10 (0.71) HSD17B10KDM4EHPGDALDH1A1NPC1
SCHEMBL14014110 0.87 KDM4E (1.00) HSD17B10KDM4EHPGDALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2023-03-30 US disclosed
CN-109311887-B Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions BIAL研发投资股份有限公司 2022-09-13 CN disclosed
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-12-07 US disclosed
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders BIAL—BioTech Investments, Inc. (PT) 2021-03-02 US disclosed
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2019-10-31 US disclosed
EP-3440080-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-02-13 EP disclosed
US-9840510-B1 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2017-12-12 US disclosed
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2017-12-07 US disclosed
WO-2017176960-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 HSD17B10 3819/4885KDM4E 1067/4885HPGD 2491/4885
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, PARK7, GAA HSD17B10 4094/4885KDM4E 889/4885HPGD 1253/4885
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 HSD17B10 4115/4885KDM4E 690/4885HPGD 1842/4885
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 HSD17B10 4115/4885KDM4E 690/4885HPGD 1842/4885
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, GAA, PARK7 HSD17B10 4037/4885KDM4E 1447/4885HPGD 1492/4885
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 HSD17B10 4115/4885KDM4E 690/4885HPGD 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.